X-linked Hypohidrotic Ectodermal Dysplasia (XLHED): Disease Characteristics Research Report

Executive summary

X-linked hypohidrotic ectodermal dysplasia (XLHED) is a rare developmental genetic disorder classically defined by the triad of hypotrichosis, hypohidrosis/anhidrosis, and hypodontia/oligodontia, reflecting abnormal formation of ectodermal appendages (hair follicles, eccrine sweat glands, teeth) due to deficiency of ectodysplasin A1 (EDA1) signaling. (aftab2023xlinkedhypohidroticectodermal pages 1-2, callea2022extendedoverviewof pages 2-4)

A key 2024 advance is improved molecular diagnostic strategy evidence supporting phenotype-guided targeted sequencing (EDA/EDAR) for “classical triad” presentations and exome-scale testing for atypical cases, with copy-number variation (CNV) detection as an important contributor to missed diagnoses. (kim2024geneticprofilingand pages 1-2, kim2024geneticprofilingand pages 7-8)

A major translational development is prenatal protein replacement for affected male fetuses using intra-amniotic delivery of an EDA1 replacement (Fc-EDA/EDI200; and a next-generation molecule ER004), with human compassionate-use data showing sustained restoration of sweating and ongoing multicenter trials (EDELIFE, NCT04980638). (schneider2018prenatalcorrectionof pages 3-5, NCT04980638 chunk 1)

1. Disease information

1.1 Concise overview (current understanding)

XLHED is a genetic ectodermal dysplasia in which deficiency of ectodysplasin A (EDA/EDA1) signaling disrupts epithelial–mesenchymal interactions required for appendage development, producing reduced/absent sweat glands (heat intolerance, risk of hyperthermia), sparse hair, and missing/abnormal teeth; additional recurrent respiratory, skin, and ocular complications are common. (aftab2023xlinkedhypohidroticectodermal pages 1-2, fete2014x‐linkedhypohidroticectodermal pages 2-4)

Abstract-supported definition (direct quote): XLHED is “diagnosed by the triad of decreased sweating, reduced hair, and hypodontia.” (fete2014x‐linkedhypohidroticectodermal pages 1-2)

1.2 Key identifiers and synonyms

Table: This table compiles the main nomenclature and database identifiers for X-linked hypohidrotic ectodermal dysplasia, including disease and gene OMIM numbers, MONDO, ICD-10, and MeSH. It is useful for harmonizing disease records across clinical, ontology, and literature sources.

Evidence source type note: identifiers are derived from aggregated disease resources (registry-based epidemiology and patient registries), and trial registries (ClinicalTrials.gov), rather than individual EHR-only sources. (nguyennielsen2013theprevalenceof pages 1-2, fete2014x‐linkedhypohidroticectodermal pages 1-2, NCT04980638 chunk 1)

2. Etiology

2.1 Disease causal factors

Primary cause: pathogenic loss-of-function variants in EDA (ectodysplasin A; EDA1 isoform) causing deficiency of EDA1 signaling, inherited in an X-linked manner in XLHED. (schneider2022ectodermaldysplasiasnew pages 1-2, nguyennielsen2013theprevalenceof pages 1-2)

Related hypohidrotic ectodermal dysplasia genes (non-X-linked forms): EDAR, EDARADD, WNT10A are frequently implicated in hypohidrotic ED broadly (with EDAR/EDARADD capable of dominant or recessive forms; WNT10A often recessive). (aftab2023xlinkedhypohidroticectodermal pages 1-2, kovalskaia2023molecularbasisand pages 1-2)

2.2 Risk factors

The principal risk factor is carriage of a pathogenic EDA variant in a family (X-linked inheritance), with males generally more severely affected and females showing variable expressivity. (aftab2023xlinkedhypohidroticectodermal pages 1-2, fete2014x‐linkedhypohidroticectodermal pages 2-4)

2.3 Protective factors

No specific genetic or environmental protective factors were identified in the retrieved primary sources.

2.4 Gene–environment interactions

Direct gene–environment interaction evidence (formal GxE) was not identified in the retrieved sources. Clinically, environmental heat exposure interacts with anhidrosis to precipitate hyperthermia risk (a clinically important interaction, though not studied as GxE). (schneider2018prenatalcorrectionof pages 1-2, nguyennielsen2013theprevalenceof pages 1-2)

3. Phenotypes

3.1 Core phenotypes, characteristics, and HPO mapping

Below are major phenotypes (symptoms/signs) with suggested HPO terms and evidence.

1) Hypohidrosis/anhidrosis and heat intolerance - Type: clinical sign/functional deficit - Onset: typically infancy/early childhood (early clinical recognition), though diagnosis may be delayed. (nguyennielsen2013theprevalenceof pages 1-2, aftab2023xlinkedhypohidroticectodermal pages 1-2) - Severity: ranges from absent sweating to low residual sweating depending on genotype. (schneider2011sweatingabilityand pages 5-10) - Key complications: life-threatening hyperthermia. (schneider2018prenatalcorrectionof pages 1-2) - Suggested HPO: HP:0000973 (Anhidrosis), HP:0003214 (Hypohidrosis), HP:0002044 (Hyperthermia), HP:0004370 (Heat intolerance) - Quantitative biomarker data (sweat testing): in controls, mean pilocarpine-stimulated sweat volume was 72 µL (range 29–93 µL) and mean sweat pore density 455 pores/cm² (294–900). In XLHED males, 14/31 had no pores/no inducible sweating; 7/31 produced 1–11 µL (low sweating). (schneider2011sweatingabilityand pages 5-10, schneider2011sweatingabilityand pages 1-5)

2) Hypodontia/oligodontia (abnormal or missing teeth) - Type: physical manifestation - Onset: developmental (childhood; detection with tooth development) - Frequency (registry-reported): hypodontia reported in 89% overall of XLHED respondents in EDIR, and in 74% of male XLHED registrants in one registry analysis. (fete2014x‐linkedhypohidroticectodermal pages 1-2) - Suggested HPO: HP:0000668 (Hypodontia), HP:0000674 (Oligodontia), HP:0006480 (Abnormality of dental morphology)

3) Hypotrichosis / sparse scalp hair and eyebrows - Type: physical manifestation - Frequency (registry-reported): reduced hair reported in 74% overall in EDIR and 80% of male XLHED registrants; in females, hair abnormalities still reported by the majority (63% in EDIR). (fete2014x‐linkedhypohidroticectodermal pages 1-2, fete2014x‐linkedhypohidroticectodermal pages 2-4) - Suggested HPO: HP:0001006 (Hypotrichosis), HP:0000535 (Sparse eyebrow)

4) Recurrent respiratory/nasal complications - Type: symptoms/clinical signs - Frequency (international patient registry, males): foul-smelling nasal discharge 67%, infections requiring antibiotics 52%, recurrent pneumonias 19%, wheeze 66%, recurrent sinusitis 49%, raspy/hoarse voice 67%. (fete2014x‐linkedhypohidroticectodermal pages 2-4) - Suggested HPO: HP:0002789 (Recurrent respiratory infections), HP:0001742 (Chronic sinusitis), HP:0002099 (Wheezing), HP:0001609 (Hoarse voice), HP:0011950 (Nasal discharge)

5) Eczema / dry skin - Type: clinical sign - Frequency (EDIR): eczema reported in 66% males and 40% females in registry summary excerpt. (fete2014x‐linkedhypohidroticectodermal pages 1-2) - Suggested HPO: HP:0000964 (Eczema), HP:0000958 (Dry skin)

6) Ocular surface disease / dry eye - Type: symptom/clinical sign - Frequency: “nearly one-third” affected with ocular dry eye in registry excerpt. (fete2014x‐linkedhypohidroticectodermal pages 2-4) - Suggested HPO: HP:0001097 (Dry eye), HP:0000508 (Photophobia) (frequently associated per ocular review context) (callea2022extendedoverviewof pages 2-4)

3.2 Quality-of-life impact

Quality of life is substantially impacted through heat avoidance/thermoregulation constraints, need for long-term dental rehabilitation, recurrent ENT/respiratory issues, and ocular surface disease requiring surveillance and ongoing supportive care. (aftab2023xlinkedhypohidroticectodermal pages 8-9, callea2022extendedoverviewof pages 2-4, fete2014x‐linkedhypohidroticectodermal pages 2-4)

4. Genetic / molecular information

4.1 Causal genes

• EDA (ectodysplasin A; EDA1 isoform critical): primary XLHED gene. (schneider2022ectodermaldysplasiasnew pages 1-2, nguyennielsen2013theprevalenceof pages 1-2)
• EDAR / EDARADD: receptors/adaptors in the same pathway; typically relevant to non-X-linked hypohidrotic ED, but central mechanistically. (callea2022extendedoverviewof pages 2-4)

4.2 Pathogenic variants and functional consequences

Variant classes: deletions, nonsense, frameshift, splice-site, and missense variants affecting key functional domains (furin cleavage site, TNF homology domain, collagen-like repeats) correlate with absent versus residual sweating. (schneider2011sweatingabilityand pages 5-10)

Genotype–phenotype mapping (example evidence): missense variants disrupting the furin recognition site (R153C/R155C/R156H) and certain TNF-domain mutations (e.g., Y304C) are linked to anhidrosis, whereas some variants (e.g., V262F, R276C, G299R, R69L) can be associated with residual sweating. (schneider2011sweatingabilityand pages 5-10)

4.3 Penetrance/expressivity and modifiers

Female heterozygotes can have clinically significant symptoms with high variability (variable expressivity). (fete2014x‐linkedhypohidroticectodermal pages 2-4)

Evidence for specific modifier genes was not identified in the retrieved sources; however, the 2024 Korean cohort emphasizes that phenotype (complete triad vs incomplete) strongly predicts detection of EDA/EDAR mutations, suggesting clinical heterogeneity may partly reflect genetic heterogeneity and structural variants (CNVs). (kim2024geneticprofilingand pages 7-8, kim2024geneticprofilingand pages 1-2)

4.4 Epigenetic information

Explicit epigenetic mechanisms for XLHED were not identified in the retrieved sources.

4.5 Chromosomal abnormalities

Large deletions/CNVs affecting EDA contribute to disease and can be missed without CNV-aware analysis (e.g., MLPA/WGS). In the 2024 Korean ED cohort, 23.1% (3/13) of EDA-positive cases had CNVs. (kim2024geneticprofilingand pages 1-2)

5. Environmental information

No specific toxin/lifestyle/infectious causal factors were identified; the disease is primarily genetic. Key environmental management issue is heat exposure, which is clinically dangerous in anhidrotic patients. (schneider2018prenatalcorrectionof pages 1-2)

6. Mechanism / pathophysiology

6.1 Core pathway (causal chain)

1) Upstream trigger: germline pathogenic EDA variant → deficiency of functional EDA1 ligand. (schneider2018prenatalcorrectionof pages 1-2) 2) Signal transduction: EDA1 binds EDAR, recruits EDARADD, and activates a TNF-like signaling cascade culminating in NF-κB activation. (callea2022extendedoverviewof pages 2-4) 3) Developmental consequence: impaired epithelial–mesenchymal signaling in placodes → failed/aborted development of ectodermal appendages (eccrine sweat glands, teeth, hair follicles, meibomian glands). (callea2022extendedoverviewof pages 2-4, schneider2018prenatalcorrectionof pages 1-2) 4) Clinical manifestations: anhidrosis/hypohidrosis → heat intolerance/hyperthermia risk; hypodontia/oligodontia → chewing/speech/esthetic impacts; hypotrichosis; frequent ENT/respiratory problems likely related to glandular/epithelial abnormalities. (fete2014x‐linkedhypohidroticectodermal pages 2-4, schneider2018prenatalcorrectionof pages 1-2)

6.2 Developmental timing (critical window)

Human eccrine sweat gland morphogenesis has a defined fetal window: “key developmental events” occur in gestational weeks 20–30, motivating prenatal replacement therapy to rescue sweat gland formation. (schneider2022ectodermaldysplasiasnew pages 2-4)

6.3 Crosstalk with WNT/β-catenin (emerging mechanistic synthesis)

Mechanistic synthesis from recent literature indicates reciprocal reinforcement between EDA–EDAR–NF-κB signaling and WNT/β-catenin activity during placode development (e.g., Wnt10b as an NF-κB target; Wnt signaling upregulating Edar). This is commonly inferred from mouse developmental and single-cell analyses and provides a plausible mechanism linking EDA deficiency to broader appendage patterning defects. (jakhar2025interplaybetweenedaedar pages 5-7, jakhar2025interplaybetweenedaedar pages 2-4)

6.4 Suggested ontology terms

• GO biological processes (suggested): ectodermal appendage development; sweat gland development; tooth development; hair follicle development; epithelial–mesenchymal signaling; NF-κB signaling
• CL cell types (suggested): keratinocyte (epidermal basal keratinocyte); odontogenic epithelial cell; dermal papilla cell; myoepithelial cell (sweat gland)

(These are ontology suggestions aligned with the mechanisms described in the cited sources. (callea2022extendedoverviewof pages 2-4, schneider2022ectodermaldysplasiasnew pages 2-4, jakhar2025interplaybetweenedaedar pages 2-4))

7. Anatomical structures affected

7.1 Organ/tissue targets (with ontology suggestions)

• Skin (UBERON:0002097) with eccrine sweat glands and hair follicles affected (reduced/absent sweat glands; hypotrichosis). (aftab2023xlinkedhypohidroticectodermal pages 1-2, schneider2022ectodermaldysplasiasnew pages 2-4)
• Dentition / tooth germs (UBERON:0001759 tooth) with hypodontia/oligodontia. (fete2014x‐linkedhypohidroticectodermal pages 1-2, schneider2018prenatalcorrectionof pages 3-5)
• Upper airway/nasal structures with chronic nasal discharge/sinusitis and respiratory complications. (fete2014x‐linkedhypohidroticectodermal pages 2-4)
• Eye and adnexa: meibomian glands and ocular surface impacted (dry eye risk; meibomian gland endpoints included in EDELIFE). (NCT04980638 chunk 1, callea2022extendedoverviewof pages 2-4)

7.2 Subcellular localization

Not specifically addressed in the retrieved sources beyond EDA being a transmembrane TNF-family ligand that is cleaved and released (a secreted signaling moiety). (schneider2022ectodermaldysplasiasnew pages 2-4)

8. Temporal development

8.1 Onset

Clinical manifestations often begin in infancy/early childhood; one clinical summary reports symptom onset between “one month to 23 months.” (aftab2023xlinkedhypohidroticectodermal pages 1-2)

8.2 Progression and course

The disease is lifelong; some severe early-life risks (hyperthermia) can be mitigated with recognition and management. Registry data describe “life-long XLHED clinical complications” such as sinus infections, eczema, wheezing, and hoarse voice. (fete2014x‐linkedhypohidroticectodermal pages 1-2)

9. Inheritance and population

9.1 Inheritance

Predominantly X-linked (males more severely affected; females variably affected). (aftab2023xlinkedhypohidroticectodermal pages 1-2, fete2014x‐linkedhypohidroticectodermal pages 2-4)

9.2 Epidemiology (recent statistics from studies)

• Denmark (nationwide registry ascertainment, prevalence as of Jan 1, 2011): prevalence 1.6 per 100,000 for molecularly confirmed XLHED; broader HED/possible HED ascertainment yielded higher cumulative prevalence estimates (all categories 21.9 per 100,000). The study used ICD-10 Q82.4 for clinically diagnosed cases and confirmed XLHED by EDA mutation. (nguyennielsen2013theprevalenceof pages 1-2, nguyennielsen2013theprevalenceof pages 2-3)

Expert interpretation: the very large difference between molecularly confirmed prevalence and broader algorithm-defined HED prevalence implies substantial under-confirmation (genetic testing gaps) and/or misclassification when relying on administrative codes alone, supporting current emphasis on molecular confirmation and CNV-aware testing. (nguyennielsen2013theprevalenceof pages 1-2, kim2024geneticprofilingand pages 1-2)

10. Diagnostics

10.1 Clinical recognition

Diagnosis is often based on the triad (sweat, hair, teeth) and characteristic facies/complications. (fete2014x‐linkedhypohidroticectodermal pages 1-2, aftab2023xlinkedhypohidroticectodermal pages 1-2)

10.2 Functional sweating tests (quantitative biomarker)

Pilocarpine-induced sweat testing plus sweat pore density assessment is a quantifiable biomarker approach. - In Schneider et al. (2011), sweat pore count sensitivity for identifying affected males was 94% in children and 92% in adults, with clear quantitative separation from controls. (schneider2011sweatingabilityand pages 5-10) - Controls showed mean sweat volume 72 µL and mean sweat pore density 455 pores/cm², whereas many XLHED males had absent pores and 0 sweat, and low-sweating males produced 1–11 µL. (schneider2011sweatingabilityand pages 5-10, schneider2011sweatingabilityand pages 1-5)

10.3 Genetic testing approaches (2024 evidence-based strategy)

2024 cohort evidence (Korea, Orphanet J Rare Dis; published 2024-09-?? per journal issue metadata): - Overall diagnostic yield: 74.1% (20/27) mutation-positive. (kim2024geneticprofilingand pages 1-2) - Among positives, 80% (16/20) had EDA or EDAR mutations; 23.1% (3/13) of EDA-positive cases had CNVs. (kim2024geneticprofilingand pages 1-2) - Phenotype predicts yield: 94.1% of patients with the complete triad (hair/skin/dental) had detectable EDA/EDAR mutations, vs 0% when those three symptoms were not all present. (kim2024geneticprofilingand pages 7-8, kim2024geneticprofilingand pages 1-2)

Direct abstract quote (diagnostic strategy conclusion): “When conducting molecular diagnostics for ED, opting for targeted sequencing of EDA/EDAR mutations is advisable for cases with classical symptoms, while WES is deemed an effective strategy for cases in which these symptoms are absent.” (kim2024geneticprofilingand pages 1-2)

10.4 Prenatal diagnosis (emerging real-world implementation)

Prenatal ultrasound-based tooth germ counting can support non-invasive fetal assessment in at-risk pregnancies; this approach is used in trial screening and was part of the diagnostic workup for prenatal therapy. (schneider2022ectodermaldysplasiasnew pages 1-2, schneider2018prenatalcorrectionof pages 1-2)

10.5 Differential diagnosis

A case-based review highlights the need to distinguish XLHED from other ectodermal dysplasias and syndromes (e.g., EEC syndrome) and acquired hypohidrosis causes, emphasizing clinical and molecular confirmation. (aftab2023xlinkedhypohidroticectodermal pages 8-9)

11. Outcome / prognosis

11.1 Key risks and complications

• Hyperthermia risk in infancy/childhood due to inability to sweat is emphasized as potentially life-threatening. (schneider2018prenatalcorrectionof pages 1-2, nguyennielsen2013theprevalenceof pages 1-2)
• Chronic ENT/respiratory morbidity is common (registry-based frequencies summarized above). (fete2014x‐linkedhypohidroticectodermal pages 2-4)

11.2 Registry-based mortality signal

In EDIR registry analysis, 21% of XLHED registrants reported a family history of infant or childhood deaths, stated as consistent with published mortality data. (fete2014x‐linkedhypohidroticectodermal pages 1-2)

12. Treatment

12.1 Supportive and multidisciplinary care (current standard)

Current routine care is largely supportive and preventive, including thermoregulation/heat avoidance strategies, dental rehabilitation (prosthodontics/implants), dermatologic management (eczema/dry skin), ENT/pulmonary management for recurrent infections, and ophthalmic care for dry eye/ocular surface disease. (aftab2023xlinkedhypohidroticectodermal pages 8-9, callea2022extendedoverviewof pages 2-4)

Suggested MAXO terms (examples): supportive care; dental prosthesis placement; management of hyperthermia; skin emollient therapy; artificial tears / ocular surface lubrication; respiratory infection prevention.

12.2 Advanced therapeutics: EDA1 protein replacement

12.2.1 Prenatal intra-amniotic Fc-EDA (EDI200) – human compassionate-use evidence

Schneider et al. (NEJM, 2018-04-26) reported intra-amniotic administration of Fc-EDA (EDI200) to 3 affected male fetuses. - Dosing (twins): 100 mg/kg estimated fetal body weight at gestational week 26 and again at week 31. (schneider2018prenatalcorrectionof pages 3-5) - Evidence of fetal uptake: cord-blood Fc-EDA measurable 7 days after administration (62.4 and 932 ng/mL). (schneider2018prenatalcorrectionof pages 3-5) - Efficacy endpoints: treated infants had normal sweat-duct density and “normal pilocarpine-induced sweating at 6 months,” with no hyperthermic episodes or respiratory-related hospitalizations over 22 months in the twin case. (schneider2018prenatalcorrectionof pages 3-5) - Quote (author conclusion): “Prenatal treatment with Fc-EDA restored sustained sweating ability in human patients with EDA mutations that abrogate perspiration.” (schneider2018prenatalcorrectionof pages 5-7)

Visual evidence: Figure 1 from the NEJM report shows the contrast between untreated XLHED (no sweat pores/0 µL sweat) and treated infant vs healthy control for sweat pores and sweat volume outcomes. (schneider2018prenatalcorrectionof media 9c02cda0)

12.2.2 Postnatal Fc-EDA trials (limited efficacy window)

A translational review notes that postnatal dosing in infants did not successfully induce sweat ducts or sweating, consistent with a restricted developmental window for eccrine gland morphogenesis. (schneider2022ectodermaldysplasiasnew pages 2-4)

12.2.3 ER004 (prenatal intra-amniotic EDELIFE trial; ongoing)

ClinicalTrials.gov describes ER004 as an “EDA1 replacement” designed for high-affinity EDAR binding. - Design: Phase 2, open-label, genotype-match controlled; 3 intra-amniotic injections ~3 weeks apart starting gestational week 26 at 100 mg/kg estimated fetal weight per injection. (NCT04980638 chunk 1) - Primary endpoint: mean sweat volume at 6 months (pilocarpine-induced). (NCT04980638 chunk 1) - Secondary endpoints include: sweat pore density, dental development, meibomian glands, ocular outcomes, hospitalizations for hyperthermia/infections. (NCT04980638 chunk 1)

Expert analysis: the trial’s inclusion of objective sweating endpoints (sweat volume and pore density) and longer follow-up (to age 5) directly addresses prior limitations of early small compassionate-use series and aligns with validated sweat biomarkers (pilocarpine iontophoresis, pore counts) used in genotype–phenotype work. (NCT04980638 chunk 1, schneider2011sweatingabilityand pages 5-10)

13. Prevention

13.1 Primary prevention

No primary prevention exists for germline XLHED beyond reproductive options.

13.2 Secondary/tertiary prevention (complication avoidance)

Key complication prevention includes early diagnosis, anticipatory guidance for fever/heat exposure, and early dental/ENT/ophthalmic interventions to prevent downstream morbidity. (aftab2023xlinkedhypohidroticectodermal pages 8-9, callea2022extendedoverviewof pages 2-4)

13.3 Genetic counseling and reproductive options

Given X-linked inheritance and severe male phenotype, cascade testing and counseling are central. Prenatal ultrasound screening (tooth germ assessment) is used clinically and in trial screening as a non-invasive diagnostic tool in at-risk pregnancies. (schneider2022ectodermaldysplasiasnew pages 1-2, schneider2018prenatalcorrectionof pages 1-2)

14. Other species / natural disease

Naturally occurring EDA-related hypohidrotic ectodermal dysplasia has been reported across species, supporting conserved biology. - Cat (first report, 2024-06): a male cat with alopecia and tooth anomalies had a hemizygous EDA missense variant; the paper notes EDA loss-of-function variants cause HED in humans, mice, dogs, and cattle and extends this to cats. (rietmann2024edamissensevariant pages 1-2) - Cattle (historic): evidence cited for bovine anhidrotic ED caused by deletion of exon 3 of the bovine ED1 gene (EDA ortholog). (rietmann2024edamissensevariant pages 2-4)

NCBI Taxonomy identifiers were not provided in the retrieved excerpts.

15. Model organisms

15.1 Tabby mouse (murine Eda model)

The Tabby mouse is a canonical model of EDA deficiency used to study ectodermal appendage development and therapeutic rescue by prenatal EDA replacement; mechanistic work in the NEJM report also used Eda-deficient mice to show neonatal Fc receptor–dependent fetal uptake after intra-amniotic therapy. (schneider2018prenatalcorrectionof pages 2-3, schneider2018prenatalcorrectionof pages 3-5)

15.2 Translational large-animal models

Dog models of XLHED have been used for prenatal recombinant EDA1 administration, with improvements reported across multiple ectodermal structures, supporting translational relevance to prenatal therapy. (aftab2023xlinkedhypohidroticectodermal pages 8-9)

Notes on evidence gaps

• Orphanet identifiers, ICD-11, and MeSH terms beyond those in ClinicalTrials.gov were not directly extractable from the retrieved texts.
• PMIDs were not present in the excerpts provided for most papers (NEJM/Orphanet/Cureus); therefore, this report cites DOIs/URLs and publication month/year as available in-source.

Key sources (with URLs and dates)

• Schneider H. Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia. N Engl J Med. 2018-04-26. https://doi.org/10.1056/NEJMoa1714322 (schneider2018prenatalcorrectionof pages 1-2, schneider2018prenatalcorrectionof pages 3-5)
• Kim MJ et al. Genetic profiling and diagnostic strategies for patients with ectodermal dysplasias in Korea. Orphanet J Rare Dis. 2024 (volume 19:329; published 2024). https://doi.org/10.1186/s13023-024-03331-6 (kim2024geneticprofilingand pages 1-2)
• Nguyen-Nielsen M et al. The prevalence of XLHED in Denmark, 1995–2010. Eur J Med Genet. 2013-05. https://doi.org/10.1016/j.ejmg.2013.01.012 (nguyennielsen2013theprevalenceof pages 1-2)
• Fete M et al. XLHED: Clinical and diagnostic insights from an international patient registry. Am J Med Genet A. 2014-10. https://doi.org/10.1002/ajmg.a.36436 (fete2014x‐linkedhypohidroticectodermal pages 1-2)
• ClinicalTrials.gov. EDELIFE: Intraamniotic Administrations of ER004… NCT04980638. Updated 2025-04-30. https://clinicaltrials.gov/study/NCT04980638 (NCT04980638 chunk 1)
• Schneider H et al. Sweating ability and genotype in individuals with XLHED. J Med Genet. 2011-02. https://doi.org/10.1136/jmg.2010.084012 (schneider2011sweatingabilityand pages 5-10)

References

1. (aftab2023xlinkedhypohidroticectodermal pages 1-2): Hammad Aftab, Ivan A Escudero, and Fatin Sahhar. X-linked hypohidrotic ectodermal dysplasia (xlhed): a case report and overview of the diagnosis and multidisciplinary modality treatments. Cureus, Jun 2023. URL: https://doi.org/10.7759/cureus.40383, doi:10.7759/cureus.40383. This article has 10 citations.

2. (callea2022extendedoverviewof pages 2-4): Michele Callea, Stefano Bignotti, Francesco Semeraro, Francisco Cammarata-Scalisi, Jinia El-Feghaly, Antonino Morabito, Vito Romano, and Colin E. Willoughby. Extended overview of ocular phenotype with recent advances in hypohidrotic ectodermal dysplasia. Children, 9:1357, Sep 2022. URL: https://doi.org/10.3390/children9091357, doi:10.3390/children9091357. This article has 9 citations.

3. (kim2024geneticprofilingand pages 1-2): Man Jin Kim, Jee-Soo Lee, Seung Won Chae, Sung Im Cho, Jangsup Moon, Jung Min Ko, Jong-Hee Chae, and Moon-Woo Seong. Genetic profiling and diagnostic strategies for patients with ectodermal dysplasias in korea. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03331-6, doi:10.1186/s13023-024-03331-6. This article has 1 citations and is from a peer-reviewed journal.

4. (kim2024geneticprofilingand pages 7-8): Man Jin Kim, Jee-Soo Lee, Seung Won Chae, Sung Im Cho, Jangsup Moon, Jung Min Ko, Jong-Hee Chae, and Moon-Woo Seong. Genetic profiling and diagnostic strategies for patients with ectodermal dysplasias in korea. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03331-6, doi:10.1186/s13023-024-03331-6. This article has 1 citations and is from a peer-reviewed journal.

5. (schneider2018prenatalcorrectionof pages 3-5): Holm Schneider, Florian Faschingbauer, Sonia Schuepbach-Mallepell, Iris Körber, Sigrun Wohlfart, Angela Dick, Mandy Wahlbuhl, Christine Kowalczyk-Quintas, Michele Vigolo, Neil Kirby, Corinna Tannert, Oliver Rompel, Wolfgang Rascher, Matthias W. Beckmann, and Pascal Schneider. Prenatal correction of x-linked hypohidrotic ectodermal dysplasia. New England Journal of Medicine, 378:1604-1610, Apr 2018. URL: https://doi.org/10.1056/nejmoa1714322, doi:10.1056/nejmoa1714322. This article has 219 citations and is from a highest quality peer-reviewed journal.

6. (NCT04980638 chunk 1): Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia. EspeRare Foundation. 2022. ClinicalTrials.gov Identifier: NCT04980638

7. (fete2014x‐linkedhypohidroticectodermal pages 2-4): Mary Fete, Julie Hermann, Jeffrey Behrens, and Kenneth M. Huttner. X‐linked hypohidrotic ectodermal dysplasia (xlhed): clinical and diagnostic insights from an international patient registry. American Journal of Medical Genetics Part A, 164:2437-2442, Oct 2014. URL: https://doi.org/10.1002/ajmg.a.36436, doi:10.1002/ajmg.a.36436. This article has 72 citations.

8. (fete2014x‐linkedhypohidroticectodermal pages 1-2): Mary Fete, Julie Hermann, Jeffrey Behrens, and Kenneth M. Huttner. X‐linked hypohidrotic ectodermal dysplasia (xlhed): clinical and diagnostic insights from an international patient registry. American Journal of Medical Genetics Part A, 164:2437-2442, Oct 2014. URL: https://doi.org/10.1002/ajmg.a.36436, doi:10.1002/ajmg.a.36436. This article has 72 citations.

9. (NCT04980638 chunk 2): Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia. EspeRare Foundation. 2022. ClinicalTrials.gov Identifier: NCT04980638

10. (nguyennielsen2013theprevalenceof pages 1-2): Mary Nguyen-Nielsen, Stine Skovbo, Dea Svaneby, Lars Pedersen, and Jon Fryzek. The prevalence of x-linked hypohidrotic ectodermal dysplasia (xlhed) in denmark, 1995-2010. European journal of medical genetics, 56 5:236-42, May 2013. URL: https://doi.org/10.1016/j.ejmg.2013.01.012, doi:10.1016/j.ejmg.2013.01.012. This article has 97 citations and is from a peer-reviewed journal.

11. (schneider2018prenatalcorrectionof pages 1-2): Holm Schneider, Florian Faschingbauer, Sonia Schuepbach-Mallepell, Iris Körber, Sigrun Wohlfart, Angela Dick, Mandy Wahlbuhl, Christine Kowalczyk-Quintas, Michele Vigolo, Neil Kirby, Corinna Tannert, Oliver Rompel, Wolfgang Rascher, Matthias W. Beckmann, and Pascal Schneider. Prenatal correction of x-linked hypohidrotic ectodermal dysplasia. New England Journal of Medicine, 378:1604-1610, Apr 2018. URL: https://doi.org/10.1056/nejmoa1714322, doi:10.1056/nejmoa1714322. This article has 219 citations and is from a highest quality peer-reviewed journal.

12. (nguyennielsen2013theprevalenceof pages 2-3): Mary Nguyen-Nielsen, Stine Skovbo, Dea Svaneby, Lars Pedersen, and Jon Fryzek. The prevalence of x-linked hypohidrotic ectodermal dysplasia (xlhed) in denmark, 1995-2010. European journal of medical genetics, 56 5:236-42, May 2013. URL: https://doi.org/10.1016/j.ejmg.2013.01.012, doi:10.1016/j.ejmg.2013.01.012. This article has 97 citations and is from a peer-reviewed journal.

13. (schneider2022ectodermaldysplasiasnew pages 1-2): Holm Schneider. Ectodermal dysplasias: new perspectives on the treatment of so far immedicable genetic disorders. Frontiers in Genetics, Sep 2022. URL: https://doi.org/10.3389/fgene.2022.1000744, doi:10.3389/fgene.2022.1000744. This article has 27 citations and is from a peer-reviewed journal.

14. (kovalskaia2023molecularbasisand pages 1-2): V. A. Kovalskaia, T. Cherevatova, A. V. Polyakov, and O. P. Ryzhkova. Molecular basis and genetics of hypohidrotic ectodermal dysplasias. Vavilov Journal of Genetics and Breeding, 27:676-683, Nov 2023. URL: https://doi.org/10.18699/vjgb-23-78, doi:10.18699/vjgb-23-78. This article has 6 citations.

15. (schneider2011sweatingabilityand pages 5-10): Holm Schneider, Johanna Hammersen, Sabine Preisler-Adams, Kenneth Huttner, Wolfgang Rascher, and Axel Bohring. Sweating ability and genotype in individuals with x-linked hypohidrotic ectodermal dysplasia. Journal of Medical Genetics, 48:426-432, Feb 2011. URL: https://doi.org/10.1136/jmg.2010.084012, doi:10.1136/jmg.2010.084012. This article has 70 citations and is from a domain leading peer-reviewed journal.

16. (schneider2011sweatingabilityand pages 1-5): Holm Schneider, Johanna Hammersen, Sabine Preisler-Adams, Kenneth Huttner, Wolfgang Rascher, and Axel Bohring. Sweating ability and genotype in individuals with x-linked hypohidrotic ectodermal dysplasia. Journal of Medical Genetics, 48:426-432, Feb 2011. URL: https://doi.org/10.1136/jmg.2010.084012, doi:10.1136/jmg.2010.084012. This article has 70 citations and is from a domain leading peer-reviewed journal.

17. (aftab2023xlinkedhypohidroticectodermal pages 8-9): Hammad Aftab, Ivan A Escudero, and Fatin Sahhar. X-linked hypohidrotic ectodermal dysplasia (xlhed): a case report and overview of the diagnosis and multidisciplinary modality treatments. Cureus, Jun 2023. URL: https://doi.org/10.7759/cureus.40383, doi:10.7759/cureus.40383. This article has 10 citations.

18. (schneider2022ectodermaldysplasiasnew pages 2-4): Holm Schneider. Ectodermal dysplasias: new perspectives on the treatment of so far immedicable genetic disorders. Frontiers in Genetics, Sep 2022. URL: https://doi.org/10.3389/fgene.2022.1000744, doi:10.3389/fgene.2022.1000744. This article has 27 citations and is from a peer-reviewed journal.

19. (jakhar2025interplaybetweenedaedar pages 5-7): Ajay Jakhar, Konrad Łukaszyk, Anna Pulawska-Czub, and Krzysztof Kobielak. Interplay between eda-edar and wnt signalling pathways in the development of skin appendages in hypohidrotic ectodermal dysplasia. Pediatria i Medycyna Rodzinna, 21:51-58, Apr 2025. URL: https://doi.org/10.15557/pimr.2025.0006, doi:10.15557/pimr.2025.0006. This article has 3 citations.

20. (jakhar2025interplaybetweenedaedar pages 2-4): Ajay Jakhar, Konrad Łukaszyk, Anna Pulawska-Czub, and Krzysztof Kobielak. Interplay between eda-edar and wnt signalling pathways in the development of skin appendages in hypohidrotic ectodermal dysplasia. Pediatria i Medycyna Rodzinna, 21:51-58, Apr 2025. URL: https://doi.org/10.15557/pimr.2025.0006, doi:10.15557/pimr.2025.0006. This article has 3 citations.

21. (schneider2018prenatalcorrectionof pages 5-7): Holm Schneider, Florian Faschingbauer, Sonia Schuepbach-Mallepell, Iris Körber, Sigrun Wohlfart, Angela Dick, Mandy Wahlbuhl, Christine Kowalczyk-Quintas, Michele Vigolo, Neil Kirby, Corinna Tannert, Oliver Rompel, Wolfgang Rascher, Matthias W. Beckmann, and Pascal Schneider. Prenatal correction of x-linked hypohidrotic ectodermal dysplasia. New England Journal of Medicine, 378:1604-1610, Apr 2018. URL: https://doi.org/10.1056/nejmoa1714322, doi:10.1056/nejmoa1714322. This article has 219 citations and is from a highest quality peer-reviewed journal.

22. (schneider2018prenatalcorrectionof media 9c02cda0): Holm Schneider, Florian Faschingbauer, Sonia Schuepbach-Mallepell, Iris Körber, Sigrun Wohlfart, Angela Dick, Mandy Wahlbuhl, Christine Kowalczyk-Quintas, Michele Vigolo, Neil Kirby, Corinna Tannert, Oliver Rompel, Wolfgang Rascher, Matthias W. Beckmann, and Pascal Schneider. Prenatal correction of x-linked hypohidrotic ectodermal dysplasia. New England Journal of Medicine, 378:1604-1610, Apr 2018. URL: https://doi.org/10.1056/nejmoa1714322, doi:10.1056/nejmoa1714322. This article has 219 citations and is from a highest quality peer-reviewed journal.

23. (rietmann2024edamissensevariant pages 1-2): Stefan J. Rietmann, Noëlle Cochet-Faivre, Helene Dropsy, Vidhya Jagannathan, Lucie Chevallier, and Tosso Leeb. Eda missense variant in a cat with x-linked hypohidrotic ectodermal dysplasia. Genes, 15:854, Jun 2024. URL: https://doi.org/10.3390/genes15070854, doi:10.3390/genes15070854. This article has 1 citations.

24. (rietmann2024edamissensevariant pages 2-4): Stefan J. Rietmann, Noëlle Cochet-Faivre, Helene Dropsy, Vidhya Jagannathan, Lucie Chevallier, and Tosso Leeb. Eda missense variant in a cat with x-linked hypohidrotic ectodermal dysplasia. Genes, 15:854, Jun 2024. URL: https://doi.org/10.3390/genes15070854, doi:10.3390/genes15070854. This article has 1 citations.

25. (schneider2018prenatalcorrectionof pages 2-3): Holm Schneider, Florian Faschingbauer, Sonia Schuepbach-Mallepell, Iris Körber, Sigrun Wohlfart, Angela Dick, Mandy Wahlbuhl, Christine Kowalczyk-Quintas, Michele Vigolo, Neil Kirby, Corinna Tannert, Oliver Rompel, Wolfgang Rascher, Matthias W. Beckmann, and Pascal Schneider. Prenatal correction of x-linked hypohidrotic ectodermal dysplasia. New England Journal of Medicine, 378:1604-1610, Apr 2018. URL: https://doi.org/10.1056/nejmoa1714322, doi:10.1056/nejmoa1714322. This article has 219 citations and is from a highest quality peer-reviewed journal.